GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » DeferredTaxAndRevenue

GHRS (GH Research) DeferredTaxAndRevenue : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GH Research DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GH Research's current deferred tax and revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

GH Research DeferredTaxAndRevenue Historical Data

The historical data trend for GH Research's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research DeferredTaxAndRevenue Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
- - - - -

GH Research Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GH Research DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of GH Research's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GH Research Business Description

Traded in Other Exchanges
Address
Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.